UZH-Logo

Maintenance Infos

Browse by Creators - Zurich Open Repository and Archive

Navigate back| Up a level
Export as
Number of items: 19.

Habermeyer, E (2009). Bearbeitung mehrerer Stichworte. In: Margraf, J; Müller-Spahn, F. Pschyrembel® Psychiatrie, Klinische Psychologie, Psychotherapie. Berlin, New York, .-..

Steinhausen, H C (2009). Bindungsstörung im Kindesalter. In: Margraf, J; Müller-Spahn, F. Pschyrembel Psychiatrie, Klinische Psychologie, Psychotherapie. Berlin: de Gruyter, xx-xx.

Steinhausen, H C (2009). Jactation. In: Margraf, J; Müller-Spahn, F. Pschyrembel Psychiatrie, Klinische Psychologie, Psychotherapie. Berlin: de Gruyter, xx-xx.

Steinhausen, H C (2009). Kindesmisshandlung. In: Margraf, J; Müller-Spahn, F. Pschyrembel Psychiatrie, Klinische Psychologie, Psychotherapie. Berlin: de Gruyter, xx-xx.

Steinhausen, H C (2009). Mutismus. In: Margraf, J; Müller-Spahn, F. Pschyrembel Psychiatrie, Klinische Psychologie, Psychotherapie. Berlin: de Gruyter, xx-xx.

Savaskan, E; Müller, S E; Böhringer, A; Philippsen, C; Müller-Spahn, F; Schächinger, H (2007). Age determines memory for face identity and expression. Psychogeriatrics, 7(2):49-57.

Walter, M; Hänni, B; Haug, M; Amrhein, I; Krebs-Roubicek, E; Müller-Spahn, F; Savaskan, E (2007). Humour therapy in patients with late-life depression or Alzheimer's disease: a pilot study. International Journal of Geriatric Psychiatry, 22(1):77-83.

Savaskan, E; Jockers, R; Ayoub, M; Angeloni, D; Fraschini, F; Flammer, J; Eckert, A; Müller-Spahn, F; Meyer, P (2007). The MT2 melatonin receptor subtype is present in human retina and decreases in Alzheimer's disease. Current Alzheimer Research, 4(1):47-51.

Brunner, P; Sözer-Topcular, N; Jockers, R; Ravid, R; Angeloni, D; Fraschini, F; Eckert, A; Müller-Spahn, F; Savaskan, E (2006). Pineal and cortical melatonin receptors MT1 and MT2 are decreased in Alzheimer's disease. European Journal of Histochemistry, 50(4):311-316.

Savaskan, E; Schnitzler, C; Schröder, C; Cajochen, C; Müller-Spahn, F; Wirz-Justice, A (2006). Treatment of behavioural, cognitive and circadian rest-activity cycle disturbances in Alzheimer's disease: haloperidol vs. quetiapine. International Journal of Neuropsychopharmacology, 9(5):507-516.

Savaskan, E; Ravid, R; Meier, F; Müller-Spahn, F; Jockers, R (2005). Immunohistochemical localization of fas-associated phosphatase-1 (FAP-1) in Alzheimer disease hippocampus. Applied Immunohistochemistry & Molecular Morphology, 13(2):190-193.

Savaskan, E; Ayoub, M A; Ravid, R; Angeloni, D; Fraschini, F; Meier, F; Eckert, A; Müller-Spahn, F; Jockers, R (2005). Reduced hippocampal MT2 melatonin receptor expression in Alzheimer's disease. Journal of Pineal Research, 38(1):10-16.

Savaskan, E; Löffler, K U; Meier, F; Müller-Spahn, F; Flammer, J; Meyer, P (2004). Immunohistochemical localization of angiotensin-converting enzyme, angiotensin II and AT1 receptor in human ocular tissues. Ophthalmic Research, 36(6):312-320.

Savaskan, E; Müller-Spahn, F; Meier, F; Wirz-Justice, A; Meyer, P (2004). Orexins and their receptors in the human retina. Pathobiology, 71(4):211-216.

Olivieri, G; Otten, U; Meier, F; Baysang, G; Dimitriades-Schmutz, B; Müller-Spahn, F; Savaskan, E (2003). Beta-amyloid modulates tyrosine kinase B receptor expression in SHSY5Y neuroblastoma cells: influence of the antioxidant melatonin. Neuroscience, 120(3):659-665.

Hofmann, M; Rösler, A; Schwarz, W; Müller-Spahn, F; Kräuchi, K; Hock, C; Seifritz, E (2003). Interactive computer-training as a therapeutic tool in Alzheimer's disease. Comprehensive Psychiatry, 44(3):213-219.

Savaskan, E; Olivieri, G; Meier, F; Seifritz, E; Wirz-Justice, A; Müller-Spahn, F (2003). Red wine ingredient resveratrol protects from beta-amyloid neurotoxicity. Gerontology, 49(6):380-383.

Rehm, J (2003). Scientific evaluations of opioid-assisted substitution treatment. In: Kuntze, M F; Müller-Spahn, F; Ladewig, D; Bullinger, A H. Basic and clinical science of opioid addiction. Bibliotheca Psychiatrica. Basel: Karger, 33-38.

Hock, C; Maddalena, A; Raschig, A; Müller-Spahn, F; Eschweiler, G; Hager, K; Heuser, I; Hampel, H; Müller-Thomsen, T; Oertel, W; Wienrich, M; Signorell, A; Gonzalez-Agosti, C; Nitsch, R M (2003). Treatment with the selective muscarinic m1 agonist talsaclidine decreases cerebrospinal fluid levels of A beta 42 in patients with Alzheimer's disease. Amyloid, 10(1):1-6.

This list was generated on Thu Jul 27 19:23:03 2017 CEST.